Health Canada is requesting industry input through a Cost-Benefit Analysis survey as part of its Red Tape Reduction Initiative for Natural Health Products (NHPs). Responses are due September 25, 2026. The survey asks stakeholders to provide practical information on how proposed changes could affect licensing, labelling, post-market obligations, GMP notifications, site licensing, and compliance costs. Health Canada is seeking evidence of where requirements create cost, delay, or administrative burden, and where proposed flexibilities may reduce that burden while maintaining consumer protection. Companies that manufacture, import, package, label, distribute, or hold NHP licences should consider responding. To help industry participate, dicentra has prepared practical instructions to support completion of the survey.
Health Canada’s Red Tape Reduction Initiative for Natural Health Products represents the latest step in the modernization of Canada’s NHP regulatory framework. The proposed amendments are intended to reduce administrative burden for both industry and government while maintaining oversight that is proportionate to product risk and uncertainty.
The consultation is broad in scope. It does not address one narrow compliance issue, such as a single labelling requirement or a single fee proposal. Instead, Health Canada is seeking input on several connected areas of the Natural Health Products Regulations (NHPR), including a simplified registration pathway for certain monograph-based products, reduced submission requirements, more flexible post-market change processes, updated labelling flexibilities, targeted safety monitoring, reduced GMP notification requirements, and risk-based site licence renewals.
The Cost-Benefit Analysis survey asks companies and associations to estimate costs, savings, product volumes, administrative effort, and implementation challenges. This feedback can help determine whether the final proposal reduces unnecessary burden while preserving the policy intent of the regulations.
Health Canada’s current Red Tape Reduction Initiative should be viewed in the context of several years of regulatory evolution affecting the NHP sector. Earlier initiatives, including the Self-Care Products Framework, introduced many of the concepts that continue to appear in Health Canada’s current modernization work, including risk-based oversight, plain language labelling, Product Facts Tables, aligned evidence standards, and greater post-market oversight.
Although the Self-Care Products Framework did not proceed as originally envisioned, its objectives continued to appear in later initiatives. Health Canada’s 2022 NHP labelling amendments reflected the plain language labelling component through Product Facts Tables, minimum type size, contrast requirements, and standardized label presentation.
At the same time, Health Canada increased its focus on oversight and enforcement. The inclusion of NHPs under Vanessa’s Law expanded the Department’s ability to respond to safety and compliance issues, including through stronger enforcement tools and increased penalties. Health Canada’s NHP GMP inspection work similarly signalled a shift toward more active post-market oversight and inspection readiness.
Cost recovery became another major part of this evolution. Health Canada initially proposed cost recovery fees for NHP regulatory activities, then revised the proposal following significant industry feedback. Although the revised proposal reduced certain fees and introduced a longer phase-in period, implementation was later postponed so the proposal could be revisited alongside broader regulatory and policy adjustments.
These developments were often introduced separately, but they share a common theme: Health Canada has been reassessing how the NHP framework should operate, how much oversight is required before market entry, what information should be maintained after authorization, and how regulatory resources should be directed. The Red Tape Reduction nitiative brings those questions together under a more practical lens.
Health Canada’s survey covers multiple areas of the NHPR. The questions are organized around proposed changes that could affect both pre-market and post-market obligations. For many companies, the most relevant sections will depend on the nature of their product portfolio, the classes of products they hold, the complexity of their labels, and the activities covered by their site licence.
Health Canada is proposing a registration pathway for certain NHPs that fully align with existing Health Canada monographs. These products are currently managed as Class I or compendial applications. Under the proposal, eligible products would not require the same pre-market licensing decision before receiving an NPN or DIN-HM and entering the market. Instead, the pathway would function more like a notification system. Products outside the registration pathway would continue to be managed through product licensing.
The practical impact could be significant for companies with large portfolios of monograph-based products. Health Canada is asking respondents to estimate how many products currently align with existing monographs, how much it costs to prepare Class I applications, and what savings or sales impacts could result from faster market entry.
Health Canada is also considering reduced information submission requirements for certain products. Under the proposed registration pathway, information such as label text, finished product specifications, and the purpose of each non-medicinal ingredient may no longer need to be submitted at the time of registration.
This does not mean the information becomes irrelevant. Some requirements would shift from pre-market submission to post-market maintenance, meaning companies would still need complete, accurate, and inspection-ready documentation available upon request.
The survey asks for feedback on proposed flexibility for post-market product changes. Under the current framework, changes may require an amendment, a notification, or a new product licence application depending on the nature of the change. Health Canada is considering whether certain changes that currently require amendments could instead be submitted as notifications, including some changes to medicinal ingredient source material, certain synthetic or non-synthetic changes, and changes made to align with monograph updates.
Health Canada is also considering whether certain fundamental changes that currently require a new application could instead be managed as amendments where they do not affect efficacy, nature, or safety profile. For active portfolios, this is one of the most practical areas of the consultation because changes can arise from supplier changes, manufacturing adjustments, monograph updates, formulation refinements, label updates, or commercial decisions.
Health Canada is proposing transition approaches for existing licensed products. Certain products that meet the proposed registration pathway may be administratively transitioned to registration while maintaining the same NPN or DIN-HM.
Site information remains a key consideration. Products that have not submitted required site information may need to do so within a proposed transition period. At the end of that period, products eligible for registration but lacking required site information could be discontinued, requiring a new registration and new NPN to return to market. This makes the consultation particularly relevant for companies with older licences, legacy portfolios, or incomplete site information on file.
Labelling is one of the most important areas covered by the survey. Health Canada is considering additional flexibility related to the 2022 NHP labelling amendments, including how key product information is presented and whether a standardized Product Facts Table should remain mandatory.
Under the proposal, key product information would still need to be prominently displayed on the label, including medicinal ingredients, recommended use or purpose, warnings and allergy information, and directions for use. However, Health Canada is considering whether alternative formats could be acceptable if they meet prescribed requirements for headings, type size, font, and contrast.
The survey also addresses non-medicinal ingredient labelling, medicinal ingredient information, fragrance allergens, digital labels, leaflets, package inserts, and recommended conditions of use. These details matter because many NHP labels are constrained by small package sizes, bilingual formatting, extensive ingredient lists, multiple risk statements, or limited available label surface area.
For companies already preparing for the 2022 labelling amendments, the Red Tape Reduction Initiative may affect transition planning. Health Canada is considering extending the transition period by two years, depending on final publication timing. Companies should avoid assuming that labelling obligations are being removed. The proposed direction appears to be greater flexibility in how certain information is presented, not elimination of the underlying objective of clear consumer information.
Health Canada is proposing changes to post-market vigilance obligations. Under the current framework, licence holders must annually prepare and maintain a summary report and submit it to Health Canada when requested. The proposal would remove the annual summary report requirement and replace it with a more targeted issue-related reporting approach.
Under this model, the Minister could require a concise critical analysis of a specified safety issue where new information raises concern about the risks associated with a product. This reflects a broader risk-based approach: rather than requiring routine annual summary reports for all products, Health Canada would focus reporting obligations on specific safety issues when they arise. Companies would still need to maintain safety information and respond when required.
The survey also asks about GMP notifications and site licence renewals. Health Canada is considering reducing the number of GMP notifications required when changes are made to buildings, equipment, practices, or procedures. For site licence holders, this could reduce administrative burden where changes do not meaningfully affect compliance risk. However, companies would still need to maintain appropriate GMP controls and documentation.
Health Canada is also considering moving site licence renewals to a more risk-based system. Under the current framework, renewal periods are prescribed based on how long a person has held a licence. A risk-based approach could allow renewal expectations to better reflect compliance history, experience, and regulated activities.
Health Canada is asking stakeholders to quantify the operational and financial impact of the proposed changes. This is the central feature of the survey. The questionnaire requests information on costs to prepare Class I applications, expected savings from registration, potential sales impacts from faster market entry, amendment and notification costs, labelling update costs, vigilance record retention costs, GMP notification costs, and site licence renewal costs. It also asks for qualitative comments where quantitative data is not available.
This matters because Health Canada has indicated that the survey responses will inform the Cost-Benefit Analysis for the regulatory package. The data gathered through the survey may help the Department adjust its proposal to minimize costs while preserving the policy intent.
A company with many monograph-based products may be able to show that registration would reduce application costs and accelerate market entry. A company with small bilingual labels may explain why rigid formatting creates packaging challenges. A site licence holder may quantify the administrative cost of GMP notifications or renewals. These examples give Health Canada practical evidence of where flexibility may be appropriate.
General comments are useful, but measurable examples are more persuasive. The strongest responses will identify the requirement at issue, explain its impact, quantify cost or time where possible, and describe whether the proposed change would reduce burden without compromising safety or quality.
Companies should consider participating if they are affected by NHP licensing, labelling, site licensing, GMP compliance, or post-market obligations in Canada. The proposed amendments may affect product applications, Class I monograph-based products, post-licensing changes, discontinuation notifications, site information, Product Facts Tables, digital labelling, vigilance records, GMP notifications, and site licence renewals.
The survey is especially important for small and medium-sized businesses. Health Canada is seeking information on how proposed changes may affect different types of organizations, including small businesses. Without detailed feedback from smaller companies, the final regulatory analysis may not fully reflect the operational realities of businesses with limited regulatory, labelling, or compliance resources.
Participation also helps ensure that Health Canada hears from a broad cross-section of the NHP industry. Smaller manufacturers, importers, private label distributors, and product licence holders may have particularly important insights where administrative burden affects their ability to maintain or expand product portfolios in Canada.
Health Canada’s consultation package is comprehensive, spanning 17 pages and more than 30 questions covering product registration, licensing, labelling, post-market vigilance, GMP notifications, site licensing, and regulatory costs.
To make participation easier, dicentra is providing the original Health Canada consultation package together with a few practical notes highlighting key considerations when completing the survey, including which sections may be most relevant to different organizations and how to submit your response.
dicentra continues to monitor Health Canada’s Red Tape Reduction Initiative and related NHP regulatory developments, including cost recovery, labelling modernization, product licensing, site licensing, GMP compliance, and post-market obligations.
Our regulatory team supports NHP manufacturers, importers, brand owners, private label distributors, and site licence holders with product licensing, site licence applications and renewals, label compliance assessments, Product Facts Table strategy, post-market change assessments, GMP compliance support, regulatory gap assessments, transition planning, and strategic regulatory advice.
If your organization needs help understanding how Health Canada’s proposed NHP Red Tape Reduction Initiative changes may affect your business, contact dicentra today.